First Trust Advisors
SYRE icon

First Trust Advisors’s Spyre Therapeutics SYRE Stock Holding History

First Trust Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$868K Sell
9,779
-168,610
-95% -$12.3M ﹤0.01% 2281
2026
Q1 		$9M Buy
+178,389
New +$6.73M 0.01% 1145
2025
Q1 		– Sell
-23,550
Closed -$548K – 2619
2024
Q4 		$548K Buy
+23,550
New +$691K ﹤0.01% 2220

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

First Trust Advisors's SYRE Position: Q2 2026 in Review

First Trust Advisors reduced its Spyre Therapeutics (SYRE) stake by 95% in Q2 2026, selling an estimated $12.3M and leaving 9,779 shares worth $868K. The position accounts for ﹤0.01% of the portfolio, ranked #2281.

First Trust Advisors first reported a position in SYRE in Q4 2024 and has held it in 3 quarters since. The position peaked at $9M in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • First Trust Advisors held 9,779 shares of Spyre Therapeutics worth $868K as of Q2 2026.
  • First Trust Advisors sold 168,610 Spyre Therapeutics shares in Q2 2026, an estimated $12.3M.
  • Spyre Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #2281 holding.
  • First Trust Advisors first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • First Trust Advisors's Spyre Therapeutics position peaked at $9M in Q1 2026.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.